Foss, F M <br/><br/>
Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Dec 1992 
 - 1907-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1992.10.12.1907  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Male<br/>Middle Aged<br/>Mycosis Fungoides--drug therapy<br/>Neoplasm Staging<br/>Pentostatin--administration & dosage<br/>Recombinant Proteins<br/>Sezary Syndrome--drug therapy<br/>Skin Neoplasms--drug therapy<br/>Survival Analysis<br/>Treatment Outcome